CBAY

Cymabay Therapeutics
CBAY

Overview Fund Activity
Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

27 hedge funds and large institutions have $12M invested in Cymabay Therapeutics in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
27
Holders Change
–
Holders Change %
0%
% of All Funds
0.68%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
5
Increased
5
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
JGC
1
J. Goldman & Co
New York
$571K
2
BBA
2
Baker Bros. Advisors
New York
$535K
3
AAP
3
Ardsley Advisory Partners
Connecticut
$26K
4
AIM
4
Acrospire Investment Management
Illinois
$18K
5
Creative Planning
5
Creative Planning
Kansas
$7K

Top Sellers

1
Vanguard Group
1
Vanguard Group
Pennsylvania
$913K
2
LOAMU
2
Lombard Odier Asset Management (USA)
New York
$998K
3
VKH
3
Virtu KCG Holdings
New York
$0
4
Goldman Sachs
4
Goldman Sachs
New York
$0
5
KCM
5
Kingdon Capital Management
New York
$1.63M
Name Holding Trade Value Shares
Change 		Shares
Change %
VKH
26
Virtu KCG Holdings
New York
– -$33K -17,208 Closed
Goldman Sachs
27
Goldman Sachs
New York
– -$32K -16,554 Closed
Citadel Advisors
28
Citadel Advisors
Florida
– -$25K -12,692 Closed
Barclays
29
Barclays
United Kingdom
– -$22K -11,500 Closed
TRCT
30
Tower Research Capital (TRC)
New York
– -$1K -387 Closed
1
2